SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies

Leukemia Research

Volumn 34, Issue 8, 2010, Pages 1103-1106

  Chamba, Anita ^a   Holder, Michelle J ^a   Jarrett, Ruth F ^b   Shield, Lesley ^b   Toellner, Kai M ^a   Drayson, Mark T ^c   Barnes, Nicholas M ^c,d   Gordon, John ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Institute of Comparative Medicine   (United Kingdom)

^c MRC Centre for Immune Regulation   (United Kingdom)

^d CELENTYX LTD   (United Kingdom)

Author keywords

CD154; Leukaemia; Lymphoma; Proliferation; Serotonin transporter

Indexed keywords

CD40 LIGAND; CLOMIPRAMINE; FLUOXETINE; SEROTONIN TRANSPORTER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; FOLLICULAR LYMPHOMA; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CLOMIPRAMINE; FLUOXETINE; HUMANS; L CELLS (CELL LINE); LYMPHOMA, B-CELL; MICE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 77953614258     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.007     Document Type: Article

References (8)

1. Serafeim A., Grafton G., Chamba A., Gregory C.D., Blakely R.D., Bowery N.G., et al. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood 2002, 99:2545-2553.
2. Meredith E.J., Holder M.J., Chamba A., Challa A., Drake-Lee A., Bunce C.M., et al. The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J 2005, 19:1187-1189.
3. Chamba A., Holder M.J., Barnes N.M., Gordon J. Characterisation of the endogenous human peripheral serotonin transporter SLC6A4 reveals surface expression without N-glycosylation. J Neuroimmunol 2008, 204:75-84.
4. Serafeim A., Holder M.J., Grafton G., Chamba A., Drayson M.T., Luong Q.T., et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 2003, 15:3212-3219.
5. Barnes N.M., Gordon J. Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: evidence and aspirations. Semin Cancer Biol 2008, 18:218-225.
6. Meredith E.J., Holder M.J., Rosén A., Lee A.D., Dyer M.J., Barnes N.M., et al. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci USA 2006, 103:13485-13490.
7. Gagro A., Toellner K.M., Grafton G., Servis D., Branica S., Radojcić V., et al. Naive and memory B cells respond differentially to T-dependent signaling but display an equal potential for differentiation toward the centroblast-restricted CD77/globotriaosylceramide phenotype. Eur J Immunol 2003, 33:1889-1898.
8. Gordon J., Barnes N., Meredith E., Drayson M. In response to selective serotonin reuptake inhibitors-a new modality for the treatment of lymphoma/leukaemia? by C. Schuster, et al. [Biochem Pharmacol 2007;74:1424-1435]. Biochem Pharmacol 2008, 75(6):e1-3.